NCT00980421

Brief Summary

The purpose of study is to evaluate and compare the effect of iron supplementation when given as iron tablet or fortified biscuit or combined with zinc in the form of tablet on morbidity and iron toxicity markers among children aged 24-36 months.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
240

participants targeted

Target at P50-P75 for phase_3

Timeline
Completed

Started Oct 2009

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 18, 2009

Completed
3 days until next milestone

First Posted

Study publicly available on registry

September 21, 2009

Completed
10 days until next milestone

Study Start

First participant enrolled

October 1, 2009

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2010

Completed
Last Updated

September 21, 2009

Status Verified

September 1, 2009

Enrollment Period

10 months

First QC Date

September 18, 2009

Last Update Submit

September 18, 2009

Conditions

Keywords

ironiron toxicity markersoxidative stress markersiron supplementationNTBIiron over loadinterleukin levelsiron statusacut phase reactantspreschool children

Outcome Measures

Primary Outcomes (1)

  • The effect of intervention on immune response, iron over load, oxidative stress markers and iron status

    0 month, 1 month and 6 months

Secondary Outcomes (1)

  • Primary Outcome Measures: Mortality Incidence of disease requiring hospitalization interleukin response during severe illness or hospitalization

    180 days

Study Arms (4)

IT

EXPERIMENTAL

Iron Tablet group (12.5 mg/d) + Placebo Biscuit

Dietary Supplement: Iron Supplementation

IZ

EXPERIMENTAL

Iron (12.5mg/d)+Zinc (10 mg/d) Tablet Group + Placebo Biscuit

Dietary Supplement: Iron Supplementation

IB

EXPERIMENTAL

Iron Fortified Biscuit Group(12.5 mg/d)+ Placebo Tablet

Dietary Supplement: Iron Supplementation

CO

PLACEBO COMPARATOR

Placebo Tablet + Placebo Biscuit

Dietary Supplement: Iron Supplementation

Interventions

Iron SupplementationDIETARY_SUPPLEMENT

Iron tablet group (12.5 mg/d)+ Placebo Biscuit;Iron(12.5 mg/d)+ Zinc (10 mg/d) tablet group+ Placebo Biscuit; Iron Fortified Biscuit Group (12.5 mg/d)+ Placebo Tablet; Placebo tablet +Placebo Biscuit

Also known as: Ferrous sulphate
COIBITIZ

Eligibility Criteria

Age24 Months - 36 Months
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • between 24-36 months of age
  • not severely malnourished or ill requiring hospitalization
  • willing to stay in the study area for 6 months
  • consent to participate

You may not qualify if:

  • not consented
  • severely malnourished or ill requiring hospitalization

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Center for Micronutrient Research

Delhi, National Capital Territory of Delhi, 110024, India

Location

Related Publications (2)

  • Hoppe M, Hulthen L, Hallberg L. The relative bioavailability in humans of elemental iron powders for use in food fortification. Eur J Nutr. 2006 Feb;45(1):37-44. doi: 10.1007/s00394-005-0560-0. Epub 2005 Apr 25.

    PMID: 15864409BACKGROUND
  • Olynyk JK, Clarke SL. Iron overload impairs pro-inflammatory cytokine responses by Kupffer cells. J Gastroenterol Hepatol. 2001 Apr;16(4):438-44. doi: 10.1046/j.1440-1746.2001.02456.x.

    PMID: 11354283BACKGROUND

MeSH Terms

Conditions

Iron Overload

Interventions

ferrous sulfate

Condition Hierarchy (Ancestors)

Iron Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

  • Venugopal P Menon, PhD

    Annamalai University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Venugopal P Menon, PhD

CONTACT

Jitender Kumar, PhD

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 18, 2009

First Posted

September 21, 2009

Study Start

October 1, 2009

Primary Completion

August 1, 2010

Study Completion

August 1, 2010

Last Updated

September 21, 2009

Record last verified: 2009-09

Locations